Education
About Us
Working with TipRanks
Follow Us
Cynata Therapeutics Limited (AU:CYP)
ASX:CYP
Total Valuation
Cynata Therapeutics Limited has a market cap or net worth of $55.80M. The enterprise value is AU$28.84M.
Market Cap$55.80M
Enterprise ValueAU$28.84M
Share Statistics
Cynata Therapeutics Limited has 237,454,380 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding237,454,380
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Cynata Therapeutics Limited’s return on equity (ROE) is -1.57 and return on invested capital (ROIC) is -108.55%.
Return on Equity (ROE)-1.57
Return on Assets (ROA)-1.30
Return on Invested Capital (ROIC)-108.55%
Return on Capital Employed (ROCE)-1.36
Revenue Per Employee10.00T>
Profits Per Employee―
Employee Count―
Asset Turnover0.26
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cynata Therapeutics Limited is ―. Cynata Therapeutics Limited’s PEG ratio is 0.21.
PE Ratio―
PS Ratio16.31
PB Ratio5.14
Price to Fair Value5.14
Price to FCF-3.51
Price to Operating Cash Flow-5.82
PEG Ratio0.21
Income Statement
In the last 12 months, Cynata Therapeutics Limited had revenue of 1.89M and earned -9.39M in profits. Earnings per share was -0.05.
Revenue1.89M
Gross Profit1.89M
Operating Income-8.12M
Pretax Income-9.39M
Net Income-9.39M
EBITDA-9.33M
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was -8.72M and capital expenditures 0.00, giving a free cash flow of -8.72M billion.
Operating Cash Flow-8.72M
Free Cash Flow-8.72M
Free Cash Flow per Share-0.04
Dividends & Yields
Cynata Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.51
52-Week Price Change-8.00%
50-Day Moving Average0.20
200-Day Moving Average0.20
Relative Strength Index (RSI)65.49
Average Volume (3m)177.93K
Important Dates
Cynata Therapeutics Limited upcoming earnings date is Feb 19, 2026, TBA (Confirmed).
Last Earnings DateAug 28, 2025
Next Earnings DateFeb 19, 2026
Ex-Dividend Date―
Financial Position
Cynata Therapeutics Limited as a current ratio of 4.40, with Debt / Equity ratio of 0.00%
Current Ratio4.40
Quick Ratio4.40
Debt to Market Cap0.00
Net Debt to EBITDA0.54
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cynata Therapeutics Limited has paid -1.89M in taxes.
Income Tax-1.89M
Effective Tax Rate0.20
Enterprise Valuation
Cynata Therapeutics Limited EV to EBITDA ratio is -2.75, with an EV/FCF ratio of -2.93.
EV to Sales13.63
EV to EBITDA-2.75
EV to Free Cash Flow-2.93
EV to Operating Cash Flow-2.95
Balance Sheet
Cynata Therapeutics Limited has $5.05M in cash and marketable securities with $0.00 in debt, giving a net cash position of $5.05M billion.
Cash & Marketable Securities$5.05M
Total Debt$0.00
Net Cash$5.05M
Net Cash Per Share$0.02
Tangible Book Value Per Share$0.02
Margins
Gross margin is 100.00%, with operating margin of -430.95%, and net profit margin of -498.14%.
Gross Margin100.00%
Operating Margin-430.95%
Pretax Margin-498.14%
Net Profit Margin-498.14%
EBITDA Margin-494.81%
EBIT Margin-509.82%
Analyst Forecast
The average price target for Cynata Therapeutics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast16.61%